These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28716053)

  • 1. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.
    Wang J; Liu X; Hong Y; Wang S; Chen P; Gu A; Guo X; Zhao P
    J Exp Clin Cancer Res; 2017 Jul; 36(1):96. PubMed ID: 28716053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
    Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
    Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib presents antitumor activity in skin cancer and induces autophagy.
    Sun FD; Wang PC; Shang J; Zou SH; Du X
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):561-566. PubMed ID: 29424919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
    Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
    Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
    Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
    J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peiminine Inhibits Glioblastoma in Vitro and in Vivo Through Cell Cycle Arrest and Autophagic Flux Blocking.
    Zhao B; Shen C; Zheng Z; Wang X; Zhao W; Chen X; Peng F; Xue L; Shu M; Hou X; Wang K; Zhong C; Sun J; Wan J; Zhao S
    Cell Physiol Biochem; 2018; 51(4):1566-1583. PubMed ID: 30497066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
    Chang HH; Cheng YC; Tsai WC; Tsao MJ; Chen Y
    Cell Physiol Biochem; 2018; 48(4):1694-1702. PubMed ID: 30078005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RND2 attenuates apoptosis and autophagy in glioblastoma cells by targeting the p38 MAPK signalling pathway.
    Xu Y; Sun Q; Yuan F; Dong H; Zhang H; Geng R; Qi Y; Xiong X; Chen Q; Liu B
    J Exp Clin Cancer Res; 2020 Aug; 39(1):174. PubMed ID: 32867814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
    Bhatt V; Alejandro L; Michael A; Ganetsky A
    Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
    Restelli V; Lupi M; Vagni M; ChilĂ  R; Bertoni F; Damia G; Carrassa L
    Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells.
    Matteoni S; Abbruzzese C; Matarrese P; De Luca G; Mileo AM; Miccadei S; Schenone S; Musumeci F; Haas TL; Sette G; Carapella CM; Amato R; Perrotti N; Signore M; Paggi MG
    J Exp Clin Cancer Res; 2019 May; 38(1):202. PubMed ID: 31101126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baicalin suppresses proliferation, migration, and invasion in human glioblastoma cells via Ca
    Zhu Y; Fang J; Wang H; Fei M; Tang T; Liu K; Niu W; Zhou Y
    Drug Des Devel Ther; 2018; 12():3247-3261. PubMed ID: 30323558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice.
    Nam HY; Nam JH; Yoon G; Lee JY; Nam Y; Kang HJ; Cho HJ; Kim J; Hoe HS
    J Neuroinflammation; 2018 Sep; 15(1):271. PubMed ID: 30231870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casticin induces apoptosis and cytoprotective autophagy while inhibiting stemness involving Akt/mTOR and JAK2/STAT3 pathways in glioblastoma.
    Yang X; Liu Z; Xu X; He M; Xiong H; Liu L
    Phytother Res; 2024 Jan; 38(1):305-320. PubMed ID: 37869765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
    Rotin LE; Gronda M; MacLean N; Hurren R; Wang X; Lin FH; Wrana J; Datti A; Barber DL; Minden MD; Slassi M; Schimmer AD
    Oncotarget; 2016 Jan; 7(3):2765-79. PubMed ID: 26624983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.